OnKure Therapeutics (OKUR) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
OKUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
OnKure Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.56 |
| 52 Week High | US$5.38 |
| 52 Week Low | US$1.91 |
| Beta | 0 |
| 1 Month Change | -28.66% |
| 3 Month Change | 34.85% |
| 1 Year Change | 58.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| OKUR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.7% | -3.0% | -0.3% |
| 1Y | 58.2% | 32.9% | 26.7% |
Return vs Industry: OKUR exceeded the US Biotechs industry which returned 28.1% over the past year.
Return vs Market: OKUR exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| OKUR volatility | |
|---|---|
| OKUR Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OKUR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OKUR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 45 | Nick Saccomano | onkuretherapeutics.com |
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
OnKure Therapeutics, Inc. Fundamentals Summary
| OKUR fundamental statistics | |
|---|---|
| Market cap | US$133.31m |
| Earnings (TTM) | -US$58.75m |
| Revenue (TTM) | n/a |
Is OKUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OKUR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$58.75m |
| Earnings | -US$58.75m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OKUR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 22:24 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OnKure Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burns | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Andrew Berens | Leerink Partners LLC |